Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VLX-1005

            Therapeutic Area: Hematology Product Name: VLX-1005

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hatteras Venture

            Deal Size: $16.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 16, 2021

            Details:

            The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAN106

            Therapeutic Area: Hematology Product Name: CAN106

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: WuXi Biologics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2021

            Details:

            CAN106 is a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 and is intended to prevent the formation of membrane attack complexes on red blood cell surfaces, thereby reducing cell lysis and other symptoms associated with PNH.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OMS906

            Therapeutic Area: Hematology Product Name: OMS906

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            The presentation included data demonstrating that a single dose of OMS906 in an animal study demonstrated a decrease of mature CFD and an increase and accumulation in pro-CFD levels that remained detectable for more than three weeks.